Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 2 AlphaBreak Trial
Details : FPI-2265 (Ac225-PSMA) is a targeted alpha therapy targeting prostate specific membrane antigen, under phase 2/3 development for patients with metastatic castration-resistant prostate cancer.
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
September 05, 2024
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fusion Pharma doses first patient in FPI-2265 prostate cancer trial
Details : FPI-2265 (Ac225-PSMA) is a targeted alpha therapy targeting prostate specific membrane antigen. It is under phase 2/3 development for metastatic castration-resistant prostate cancer.
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fusion Pharma Marks In-House Radiopharma Manufacturing Success, Details PhII/III Trial
Details : FPI-2265 (Ac225-PSMA) is a targeted alpha therapy targeting prostate specific membrane antigen, under phase 2/3 for metastatic castration-resistant prostate cancer with progressive disease.
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : $2,400.0 million
Deal Type : Acquisition
Acquisition of Fusion Pharmaceuticals Completed
Details : Through the acquisition, AstraZeneca will leverage the Fusion pipeline, which includes FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer.
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : $2,000.0 million
April 06, 2024
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : $2,400.0 million
Deal Type : Acquisition
AstraZeneca To Acquire Fusion To Accelerate Development Of Radioconjugates for Cancer
Details : The acquisition complements AstraZeneca's leading oncology portfolio including, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : $2,000.0 million
March 19, 2024
Lead Product(s) : 225-Ac FPI-2068
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : [225Ac]-FPI-2068 (FPI-2068) is a targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that express EGFR and cMET. EGFR and cMET are validated cancer targets that are co-expressed in multiple tumor types.
Product Name : FPI-2068
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : 225-Ac FPI-2068
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 225-Ac FPI-1434
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : BWX Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Details : [111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide.
Product Name : FPI-1434
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : 225-Ac FPI-1434
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : BWX Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Details : FPI-2059 is a small molecule targeted alpha therapy designed to deliver actinium-225 to tumor sites expressing neurotensin receptor 1 (NTSR1), a protein that is overexpressed in gastrointestinal, prostate, pancreatic ductal adenocarcinoma and multiple ot...
Product Name : FPI-2059
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Pepscan
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Fusion has global rights to discover, develop and commercialize any peptide-based radiopharmaceuticals, including lead program, FPI-1434 for the treatment of various solid tumors under the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Pepscan
Deal Size : Undisclosed
Deal Type : Collaboration
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs
Details : Data observed from a completed cold-antibody sub-study demonstrate potential of pre-dosing cold antibody prior to FPI-1434 ([225Ac]-FPI-1434) to increase the tumor to non-tumor distribution ratio of the radiopharmaceutical and thereby potentially improve...
Product Name : FPI-1434
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
September 06, 2022